When Does Myelogenous Leukemia Call for a Stem Cell Transplant Rather Than Drug Therapy?

The remission letter arrives, and for about a day it feels like the ending. Then the hematologist asks for another appointment and mentions, almost in passing, that a transplant coordinator will be joining. The word lands like a second diagnosis. If the chemotherapy worked, why is anyone talking about replacing the whole bone marrow?

People in that chair tend to hear the question the same way: is this because things are worse than I was told? Usually it is not. It is because leukemia doctors have learned to read the disease more finely than a blood count can show. The real question, when is transplant needed for myeloid leukemia, has a more precise answer than most people expect, and it depends far more on the biology of the leukemia cells than on how sick someone looks.

This explainer walks through that logic in plain language: what a transplant actually does, who is typically offered one, who is typically advised to hold off, and what the weeks afterward usually involve. None of it replaces the conversation with your own team. It should make that conversation easier to follow.

Myelogenous leukemia is two different diseases, and that changes everything

Start with a distinction that shapes the entire decision. “Myelogenous” (or myeloid) simply describes the family of blood cells involved: the ones that normally become red cells, platelets and the infection-fighting white cells called neutrophils. Within that family sit two very different cancers.

Acute myeloid leukemia, or AML, is a fast-moving disease in which immature myeloid cells called blasts multiply and crowd out normal blood production. Without treatment it progresses over weeks. Chronic myeloid leukemia, or CML, is a slower disease driven in almost every case by a single genetic rearrangement, the Philadelphia chromosome, which produces an abnormal signaling protein that tells cells to keep dividing.

That one difference in biology explains why the transplant question is asked so differently for each. In CML, the driver is known and can be blocked directly with a class of oral medicines called tyrosine kinase inhibitors, so transplant has become an option held in reserve. In AML there is no single switch to flip. Treatment relies on chemotherapy, sometimes with targeted drugs matched to specific mutations, and the leukemia’s own genetic profile predicts how likely it is to come back.

Some readers will also have heard the terms “bone marrow transplant” and “stem cell transplant” used interchangeably. They describe the same procedure. The blood-forming stem cells that repopulate the marrow can be collected from the marrow itself, from the bloodstream after a growth-factor injection, or from umbilical cord blood. The label “hematopoietic cell transplant” covers all three sources. The rest of this article uses “stem cell transplant” throughout and, unless stated otherwise, is talking about AML, where the decision is hardest.

What actually happens in a stem cell transplant

Strip away the jargon and a transplant for leukemia is two things happening in sequence. First, the existing bone marrow, along with any leukemia hiding in it, is deliberately suppressed or destroyed with high-dose chemotherapy, sometimes combined with total body irradiation. This preparatory step is called conditioning. Second, healthy blood-forming stem cells are infused through a central venous line, much like a blood transfusion. They travel to the marrow spaces on their own and begin producing new blood cells, a process known as engraftment.

For leukemia, the cells almost always come from another person. This is an allogeneic transplant, and the donor’s identity matters in a way that surprises many families. The new immune system that grows from donor cells is not just a replacement; it is an active participant. Donor immune cells can recognize residual leukemia as foreign and attack it, an effect hematologists call graft-versus-leukemia. That immune surveillance, not the conditioning chemotherapy alone, is a large part of why transplant can succeed where more chemotherapy would not.

The same mechanism has a shadow side. Those donor cells can also attack the recipient’s skin, gut and liver, which is graft-versus-host disease, discussed later. A great deal of modern transplant medicine is the art of keeping the helpful effect while limiting the harmful one.

Conditioning comes in different intensities. Full-intensity regimens aim to eliminate marrow completely and suit younger, fitter patients. Reduced-intensity regimens rely more on the donor immune system to do the work and have opened transplant to older adults and those with other health conditions, according to the National Cancer Institute’s AML treatment summary. Which approach is chosen, and whether the source is marrow, peripheral blood or cord blood, is a decision the transplant team makes based on the individual and the donor available.

When is transplant needed for myeloid leukemia? Start with the genetics

Here is the part that most often catches people off guard: two patients with AML who look identical on a blood count can face very different futures, and the difference is written in the chromosomes and genes of their leukemia cells.

At diagnosis, a sample of marrow is sent for cytogenetics (a look at whole chromosomes for missing, extra or rearranged pieces) and molecular testing (a search for mutations in specific genes). The results sort AML into broad prognostic groups, commonly labeled favorable, intermediate and adverse. The National Cancer Institute and Mayo Clinic both describe this risk stratification as the foundation of treatment planning.

Favorable-risk AML tends to respond durably to chemotherapy alone. For these patients, a transplant in first remission usually adds risk without clear benefit, so most guidelines advise against it unless the disease relapses. Adverse-risk AML, by contrast, has a high likelihood of returning after chemotherapy, and for these patients a transplant in first remission is typically recommended if a donor and adequate fitness are available. Intermediate-risk AML is the gray zone, where additional information, especially how completely the leukemia clears, guides the call.

Certain features push strongly toward transplant: complex chromosome abnormalities, particular high-risk mutations, AML that has evolved from a prior marrow disorder such as myelodysplastic syndrome, and AML that developed after chemotherapy or radiation for another cancer. Others pull the other way, such as specific favorable rearrangements or mutation patterns that predict lasting response to drugs.

The practical upshot is that the transplant conversation often begins before the first chemotherapy has even finished. Teams frequently start a donor search at diagnosis for anyone in the intermediate or adverse group, so that the option exists if it is needed, without committing to it.

Why measurable residual disease can tip the decision

A conventional remission is defined by what a pathologist can see under a microscope: fewer than a small threshold of blasts in the marrow and recovering normal counts. That is a meaningful milestone, but it is a coarse measure. A marrow that looks clean can still harbor leukemia cells in numbers too small to spot by eye.

Measurable residual disease, usually shortened to MRD, is the name for that hidden remainder, and laboratories now detect it with far more sensitive tools. Flow cytometry identifies leukemia cells by the unusual combination of surface proteins they carry. Molecular tests amplify the specific genetic mutation found at diagnosis and track whether it is still present. Both can detect leukemia at levels well below what a microscope shows.

Why does this matter for the transplant question? Because the persistence of MRD after induction and consolidation chemotherapy is one of the strongest predictors of relapse, independent of the genetic risk group. Someone with intermediate-risk AML who becomes MRD-negative may reasonably continue with chemotherapy alone. Someone in the same risk group who stays MRD-positive is, in many programs, steered toward transplant, because the drugs have shown they cannot finish the job.

MRD is also used the other way around. For a patient with favorable-risk AML, a persistently positive molecular marker can be the signal that this particular leukemia is behaving worse than its label suggests.

The limitations deserve honesty. MRD tests vary in sensitivity between laboratories and between the different markers being tracked, not every AML has a trackable mutation, and a negative result reduces but does not eliminate relapse risk. Your team will tell you which method is being used and what a result means in your specific case. Treat MRD as one weighty piece of evidence, not as a verdict.

Who is usually offered a stem cell transplant for AML, and who is usually asked to wait

Set the biology alongside the person, and a pattern emerges that most transplant programs follow.

People commonly offered a transplant in first remission include those with adverse-risk genetics; those with intermediate-risk disease who remain MRD-positive after chemotherapy; those whose AML arose from a prior marrow disorder or from earlier cancer treatment; and those who needed more than one round of induction to reach remission. In each case the reasoning is the same: the probability of relapse with drugs alone is judged high enough to justify the substantial risks of the procedure.

People commonly asked to wait, meaning to continue drug therapy and keep transplant as a fallback, include those with favorable-risk genetics who clear their MRD, and those with intermediate-risk disease who reach a deep, MRD-negative remission. For them the calculation flips. A transplant carries its own risk of serious complications, and if chemotherapy is likely to hold the disease, exposing someone to that risk up front is hard to justify.

A third group exists as well: people for whom transplant is judged not appropriate at any point, at least for now. Reasons usually center on fitness. Advanced organ disease of the heart, lungs, liver or kidneys, uncontrolled infection, or a level of frailty that would make conditioning dangerous can all weigh against it. Age on its own is a weaker barrier than it once was, because reduced-intensity conditioning has made transplant feasible for many older adults, as the NCI treatment summary notes. Fitness is assessed with formal scoring tools, organ function tests and sometimes a geriatric evaluation, not by a glance across the desk.

Finally, patients whose AML relapses after chemotherapy, or who never reach remission at all, are often reconsidered for transplant once the disease is brought back under control, since drugs alone have already demonstrated their limits.

CML transplant vs TKI: why the answer flipped

A generation ago, an allogeneic transplant was the standard route to long-term control of chronic myeloid leukemia for anyone young enough to attempt it. That is no longer true, and understanding why makes the CML picture much clearer.

The turning point was the development of tyrosine kinase inhibitors, or TKIs. These oral medicines block the abnormal signaling protein produced by the Philadelphia chromosome, the engine driving CML. Because the disease depends so completely on that one protein, blocking it can restore near-normal blood production in most people, and many remain in remission for years while continuing the tablets. The National Cancer Institute’s CML treatment summary describes TKIs as the usual first treatment for chronic-phase disease, with transplant considered only in specific circumstances.

Those circumstances fall into a few categories. The first is resistance: when the leukemia acquires additional mutations that prevent one TKI after another from working, transplant returns to the table. The second is intolerance: some people cannot tolerate any available TKI because of side effects, though switching between agents within the class often resolves this. The third is disease phase. CML that is diagnosed in, or progresses to, the accelerated phase or blast crisis behaves more like acute leukemia, and transplant is frequently recommended after the disease is brought back under control with drugs.

For children and young adults with CML, the question can be more nuanced because of the prospect of many decades on a daily medicine, and teams weigh this individually.

The practical message for someone newly diagnosed with chronic-phase CML is reassuring: transplant is not the expected path. Regular blood and molecular monitoring will show whether the tablets are doing their job, and the transplant question only reopens if they stop. Decisions about starting, continuing or changing a TKI rest with the prescribing hematologist.

What drug therapy for AML can and cannot do on its own

It helps to know what the non-transplant path actually involves, because the transplant decision is always made in comparison with it.

Intensive AML treatment comes in two phases. Induction is a concentrated course of chemotherapy given in hospital with the goal of clearing visible leukemia from the marrow and restoring normal blood counts; the NHS describes this phase as requiring an inpatient stay of several weeks while counts recover. Consolidation follows once remission is confirmed, and consists of further chemotherapy cycles designed to eliminate residual cells. Some patients receive a targeted drug alongside chemotherapy when their leukemia carries a matching mutation, for instance an inhibitor of the FLT3 protein or of mutant IDH enzymes, given as classes of medicine rather than one-size-fits-all.

For people who cannot tolerate intensive chemotherapy, lower-intensity options exist, typically combining a hypomethylating agent, which alters how genes are switched on and off in leukemia cells, with a drug that blocks a protein leukemia cells use to avoid dying. These regimens can produce remissions and are often given for extended periods.

What drugs alone can do: bring most patients with AML into a first remission, hold favorable-risk disease for the long term in many cases, and bridge higher-risk patients to transplant in the best possible shape.

What drugs alone struggle to do: prevent relapse in adverse-risk AML, eradicate MRD that persists after consolidation, and control leukemia that has already relapsed once. In those situations, giving more of the same treatment tends to buy time rather than durable control, which is precisely why transplant enters the conversation.

None of this means one path is universally better. It means the two paths are suited to different diseases, and the tests described earlier are how the team tells them apart. Any change to a treatment plan belongs to the treating hematologist.

Transplant or continued drug therapy: a side-by-side view

The table below summarizes how the two strategies differ in AML, drawn from the National Cancer Institute, Mayo Clinic and NHS treatment descriptions. It is a map, not a recommendation; individual circumstances can move any row.

Question	Continued drug therapy	Allogeneic stem cell transplant
Typically favored when	Favorable-risk genetics; deep, MRD-negative remission; fitness concerns that make transplant unsafe	Adverse-risk genetics; persistent MRD; relapsed disease; AML arising from prior marrow disorder or earlier cancer treatment
How it controls leukemia	Chemotherapy and targeted drugs kill dividing cells or block specific mutant proteins	Conditioning chemotherapy plus ongoing immune surveillance by donor cells (graft-versus-leukemia)
Main risks	Infection and bleeding during low counts, organ toxicity, relapse	Graft-versus-host disease, severe infection, organ toxicity, graft failure, relapse
Where treatment happens	Inpatient for induction; consolidation partly outpatient	Inpatient for conditioning and engraftment, then intensive outpatient follow-up
Recovery horizon	Months, with blood counts recovering after each cycle	Months to a year or more for immune recovery, per Mayo Clinic
Requires a donor	No	Yes: matched sibling, unrelated volunteer, half-matched relative or cord blood
If it fails	Transplant may still be possible after re-inducing remission	Options include immune-based approaches or, rarely, a second transplant

Two rows deserve emphasis. The “if it fails” line shows why many teams keep a donor search running even for patients not initially heading to transplant: the option is more valuable when it is ready. And the “main risks” line is a reminder that the comparison is not between a risky procedure and a safe one. Intensive chemotherapy carries real hazards too. The question is which set of risks is most likely to lead to lasting control for this particular leukemia in this particular person.

Finding a donor: matching, mismatch and modern options

Donor matching hinges on a set of proteins called human leukocyte antigens, or HLA, which sit on the surface of nearly every cell and act as the immune system’s identity badge. The closer the match between donor and recipient, the less likely the donor immune system is to treat the recipient’s tissues as foreign, and the less likely the recipient’s residual immune cells are to reject the graft.

Siblings are tested first because each full sibling has a one-in-four chance of being a complete HLA match, a figure the Mayo Clinic cites in its transplant overview. When no sibling matches, the search widens to volunteer registries of unrelated donors. Match likelihood depends heavily on how common a person’s HLA type is in the registry population, which is one reason people from some ancestral backgrounds wait longer or find fewer options.

Two developments have changed the landscape. Haploidentical transplantation uses a half-matched relative, typically a parent, child or sibling, made possible by newer approaches to preventing graft-versus-host disease after the cells are infused. Because nearly everyone has a half-matched relative, this has dramatically reduced the number of people who cannot find any donor. Cord blood, collected from the placenta after birth and banked, offers another source with more forgiving matching requirements, though it contains fewer cells and engrafts more slowly.

Donation itself is far less daunting than many imagine. Most donors give peripheral blood stem cells through an outpatient procedure similar to platelet donation after several days of growth-factor injections. Marrow harvest, done under anesthesia from the back of the pelvic bone, is used less often now but remains an option when the team prefers it.

Which donor and source to use is a transplant-team decision that balances match quality, donor age and health, urgency, and the recipient’s own circumstances.

What the weeks after a transplant usually look like

Ask anyone who has been through it and they will describe the same landmarks, even though every course is different.

Conditioning comes first and typically runs for about a week, during which side effects such as nausea, mouth soreness and fatigue build. The day the cells are infused is often called “day zero,” and the infusion itself is undramatic, taking an hour or two through the central line.

The hardest stretch is usually the two to three weeks that follow, while the marrow is empty and the new cells have not yet taken hold. Blood counts fall to their lowest, so infection risk is at its peak and transfusions of red cells and platelets are routine. Most people remain in hospital or in protected accommodation attached to the transplant unit throughout this period; the NHS describes the initial inpatient stay as lasting several weeks. Fevers are treated promptly and presumptively with antibiotics, since the usual signs of infection are blunted when there are almost no white cells.

Engraftment, the first sign that the new marrow is working, is marked by neutrophils reappearing in the blood, typically within a few weeks of infusion according to Mayo Clinic. Platelets follow more slowly. Discharge usually comes once counts are recovering, the person can eat and drink adequately, and any acute complications are under control.

The outpatient phase is intensive. Clinic visits may be several times a week at first, watching for graft-versus-host disease, infections and organ problems, and adjusting the immune-suppressing medicines that protect the graft. Mayo Clinic notes that full immune recovery can take a year or longer, and childhood vaccinations are typically repeated once the team judges the new immune system ready.

Fatigue outlasts almost everything else. Many people describe a slow climb back to their previous energy over many months, with good weeks and setback weeks along the way.

The risks nobody should gloss over

A responsible explainer names the hazards plainly, because they are the reason transplant is reserved for people whose leukemia is likely to return without it.

Graft-versus-host disease, or GVHD, is the signature complication. Donor immune cells recognize the recipient’s tissues as foreign and attack them. The acute form appears in the early weeks to months and most often affects the skin (rash), the gut (diarrhea, cramping) and the liver (jaundice, abnormal blood tests). The chronic form can emerge later and may involve the skin, mouth, eyes, lungs and joints, sometimes with lasting effects. Mayo Clinic describes GVHD as a leading cause of illness after allogeneic transplant. Prevention relies on immune-suppressing medicines given for months, and treatment of established GVHD typically escalates that suppression, which in turn raises infection risk.

Infection is the second major hazard, and it is not limited to the neutropenic weeks. Because the new immune system is immature and deliberately suppressed, viruses that most adults carry harmlessly, such as cytomegalovirus, can reactivate and cause serious illness. Fungal infections and pneumonia are also of particular concern. Monitoring blood for early viral reactivation and using preventive antimicrobials are standard parts of care.

Organ toxicity from conditioning can affect the liver, lungs, kidneys and heart, and the risk scales with the intensity of the regimen and the person’s baseline health. Graft failure, in which the donor cells do not establish themselves, is uncommon but serious. And relapse remains possible after transplant, particularly for adverse-risk AML, because no treatment eliminates every leukemia cell in every case.

Longer term, survivors face elevated risks of infertility, hormonal changes, cataracts, secondary cancers and cardiovascular disease, all of which are reasons transplant programs run dedicated long-term follow-up clinics. None of these risks is a reason to refuse a recommended transplant; they are the reason the recommendation is made carefully.

AML survival after bone marrow transplant: what the numbers can and cannot tell you

The most-searched questions about this topic are blunt: what are the odds of surviving AML, is it the deadliest cancer, and what is the survival rate after a transplant. They deserve a direct response, and the honest one is that a single number would mislead you.

AML is not one disease with one outlook. Published survival statistics pool together people in their twenties with favorable genetics and people in their eighties with adverse genetics and other illnesses, and the resulting average describes almost nobody. The National Cancer Institute’s treatment summary is explicit that outlook varies substantially with age, cytogenetic and molecular risk group, response to initial treatment, and whether the AML arose from a prior condition. A person who reaches an MRD-negative remission with favorable-risk disease faces a very different future from the population average, and so does someone with relapsed, adverse-risk AML.

The same caution applies to “survival after bone marrow transplant.” Reported outcomes depend on why the transplant was done, in what phase of disease, with what conditioning intensity, from what donor, and on the era in which the data were collected. Transplant practice has changed markedly, and figures from older series do not describe current care. Your team can share outcome data from the registry or trial population that most closely resembles your situation, and that is the only number worth anchoring to.

Is AML the deadliest cancer? It is a serious disease, and among the more challenging blood cancers, but it is not the cancer with the poorest outcomes overall, and many people are living years after treatment, with and without transplant. The MedlinePlus AML overview describes long-term remission as an achievable goal, particularly for younger patients and those with favorable features.

The takeaway is not to avoid the question. It is to ask it precisely: what do outcomes look like for people with my genetics, my remission status and my fitness, treated the way you are proposing to treat me?

What people often get wrong about when transplant is needed for myeloid leukemia

Several myths circulate persistently, and each can distort a decision that should rest on evidence.

“Transplant is the last resort.” In adverse-risk AML, transplant is often planned in first remission, precisely because waiting for relapse makes it less likely to work. Being offered a transplant early is a sign the team is being proactive, not that other options have run out.

“If chemo got me into remission, I don’t need anything else.” Remission means the leukemia is below the microscope’s detection threshold, not that it is gone. For higher-risk disease and for persistent MRD, remission is the window in which transplant is most effective, not a reason to skip it.

“Everyone with AML needs a transplant.” Favorable-risk AML that clears its MRD is usually treated with chemotherapy alone, and many of those patients never need a transplant. The procedure’s risks are only justified when relapse is likely without it.

“I’m too old.” Reduced-intensity conditioning has made transplant possible for many older adults, as the NCI notes. Fitness, organ function and other illnesses matter more than the number on a birthday card, and they are assessed formally.

“No sibling match means no transplant.” Unrelated donors, half-matched relatives and cord blood now cover most people who lack a matched sibling.

“CML always leads to transplant eventually.” Most people with chronic-phase CML are managed for years with tyrosine kinase inhibitors and never need one; transplant is reserved for resistance, intolerance or advanced-phase disease.

“Transplant means a new blood type and a new personality.” Blood type can indeed change to the donor’s; personality does not. The cells replace blood and immune function, nothing more.

Behind every one of these misconceptions is the same lesson: the decision turns on the leukemia’s biology and the person’s fitness, measured carefully, not on where someone is in the treatment sequence.

Questions to ask your care team

Good questions do more than gather facts. They tell the team what you care about and shape the plan accordingly. Bring someone to write down the answers, and do not be embarrassed to ask for the same explanation twice.

On the disease itself, ask which cytogenetic and molecular risk group your leukemia falls into, which specific mutations were found, and whether any of them can be tracked as an MRD marker. Ask what your MRD result was after each phase of treatment and how sensitive the test used in your laboratory is.

On the recommendation, ask why transplant is or is not being advised for you specifically, what the estimated relapse risk would be with drug therapy alone in people like you, and what would change the recommendation in either direction. If transplant is not being proposed now, ask under what circumstances it would be reconsidered and whether a donor search is underway regardless.

On the procedure, ask which conditioning intensity is planned and why, what donor options have been identified, how long the inpatient stay is expected to be, and what the plan is for preventing and monitoring graft-versus-host disease and viral reactivation.

On life afterward, ask about fertility preservation before conditioning, what the return-to-work timeline has looked like for others in your situation, which long-term effects the team watches for, and what support is available for caregivers.

Finally, ask whether a clinical trial is open that fits your situation. Trials are how transplant practice has improved, and being offered one does not mean standard care is unavailable.

If a second opinion would help you feel settled, ask for one. Hematologists expect this for a decision of this weight, and a well-run team will help arrange it rather than take offense.

When to call your doctor

Whether you are receiving chemotherapy, recovering from a transplant, or being monitored on a tyrosine kinase inhibitor, your team will give you a direct number to call day or night. Use it early rather than waiting to see how things develop. In leukemia care, the threshold for calling is deliberately low.

Contact the team immediately, or attend emergency care if you cannot reach them, for any of the following:

• A temperature at or above the threshold your team has given you, or shaking chills, even if you otherwise feel well; the NHS advises treating fever during low blood counts as an emergency.
• Any new bleeding that does not stop, blood in urine or stool, black stools, or a spreading rash of tiny red or purple spots.
• Shortness of breath, chest pain, or a new cough.
• Severe or worsening diarrhea, abdominal pain, or persistent vomiting, particularly after a transplant, when these can signal gut graft-versus-host disease or infection.
• A new skin rash, especially on the palms, soles, face or upper body after transplant.
• Yellowing of the skin or eyes, or dark urine with pale stools.
• Confusion, severe headache, sudden weakness, or difficulty speaking.
• Redness, pain, swelling or discharge around a central line, or a line that will not flush.
• Sudden pain, swelling or warmth in one leg, which can indicate a clot.

Between appointments, also let the team know about less dramatic but persistent changes: mouth sores that make eating difficult, unusual bruising, extreme fatigue that is getting worse rather than better, or anything that simply feels wrong to you. People often apologize for “bothering” the ward. Nurses and doctors in this specialty would much rather hear about a symptom that turns out to be nothing than miss one that mattered.

Every decision about investigating or treating these symptoms rests with your treating team, who know your counts, your medicines and your history.

Frequently asked questions

Does everyone with AML need a transplant?

No. Transplant is generally reserved for people whose leukemia carries adverse-risk genetics, who remain MRD-positive after chemotherapy, or whose disease has relapsed. People with favorable-risk AML who reach a deep remission are usually treated with chemotherapy alone, and many never require a transplant. The treating team makes this call using marrow genetics, MRD testing and an assessment of fitness.

What are the odds of surviving AML leukemia?

There is no single honest figure, because AML outcomes vary widely with age, the leukemia’s genetic risk group, response to initial treatment and overall health, as the National Cancer Institute’s treatment summary explains. Pooled statistics average very different situations together. Ask your hematologist what outcomes look like for people whose disease and circumstances most closely resemble yours.

Is AML the deadliest cancer?

No. AML is a serious blood cancer and among the more challenging to treat, but it is not the cancer with the poorest outcomes overall. Many people, particularly those who are younger or whose leukemia has favorable features, achieve long-term remission with chemotherapy alone or with transplant. Outlook depends far more on individual disease biology than on the diagnosis label.

What is the survival rate for AML after a bone marrow transplant?

Reported outcomes after transplant depend on the reason for transplant, the disease phase, donor type, conditioning intensity and the era of the data, so a single percentage would be misleading. Older published series do not reflect current practice. Your transplant team can share registry or trial data for people matching your risk group and remission status, which is the only figure worth anchoring to.

Has anyone survived AML leukemia?

Yes, many people have. Long-term remission is an achievable goal in AML, and it is reached both with chemotherapy alone in favorable-risk disease and with transplant in higher-risk disease. Survivorship clinics exist because a substantial population is living for years after treatment. Individual outlook depends on genetics, remission depth, age and fitness, which your team can discuss with you.

CML transplant vs TKI: which is used first?

Tyrosine kinase inhibitors are the usual first treatment for chronic-phase CML, according to the National Cancer Institute. These oral medicines block the protein driving the disease, and most people remain in remission on them for years. Transplant is considered mainly when the leukemia resists successive TKIs, when no TKI can be tolerated, or when the disease progresses to accelerated phase or blast crisis.

Why would I be offered a transplant if my chemotherapy worked?

Because remission means leukemia is below what a microscope can see, not that it is gone. If your leukemia has adverse-risk genetics or MRD testing still detects cells, the likelihood of relapse with drugs alone is judged high, and transplant is most effective when performed during remission rather than after relapse. Being offered it early reflects a proactive plan, not a hidden setback.

What happens if I have no matched sibling donor?

Most people can still proceed. Options include a matched unrelated volunteer from a registry, a half-matched (haploidentical) relative such as a parent, child or sibling, or banked umbilical cord blood. Newer approaches to preventing graft-versus-host disease have made half-matched transplants routine in many centers. Your transplant team will explain which option suits your situation and timeline.

How long does a stem cell transplant for AML take from start to recovery?

Conditioning typically lasts about a week, the infusion itself takes an hour or two, and the initial inpatient stay lasts several weeks while the new marrow engrafts, according to the NHS. Neutrophils usually reappear within a few weeks. Mayo Clinic notes that immune recovery can take a year or longer, with intensive outpatient follow-up throughout. Individual timelines vary considerably.

What is measurable residual disease and why does it matter?

Measurable residual disease, or MRD, refers to leukemia cells that persist after treatment at levels too low for a microscope to detect but detectable by sensitive flow cytometry or molecular tests. Persistent MRD after chemotherapy strongly predicts relapse, so many teams use it to decide whether a patient in remission should proceed to transplant or continue with drug therapy alone.

References

• Acute myeloid leukaemia: Treatment, NHS
• Stem cell and bone marrow transplants, NHS
• Acute myeloid leukemia, MedlinePlus Medical Encyclopedia

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.